corporate governance statement could do with an overhaul imo if they want more people to invest. Short position seems to be creeping up . http://www.shortman.com.au/stock?q=cdu
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress